Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Axi-cel in refractory large B-cell lymphoma, effects of C1 inhibitor deficiency on coagulation, and the evolution of therapy-related myeloid neoplasms

In this week’s episode we’ll report on the findings from a 5-year follow-up study of axicabtagene ciloleucel in refractory large B-cell lymphoma, discuss the role of C1 inhibitor deficiency in coagulation and venous thrombosis, and learn how chemotherapy signatures can be used to track the evolution of therapy-related myeloid neoplasms.


Released May 11, 2023

Subscribe today via iTunes   Google Play    Spotify to receive notification of each new episode as it's published.

 

The articles highlighted in this episode are listed below:

 
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals